| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
LAKE NONA, Fla.—Mid-August saw Sanford-BurnhamMedical Research Institute announce that it had entered into a collaborationwith Pfizer Inc. to identify new therapeutic targets for preventing andtreating complications of obesity and diabetes. Specifically, the team will usenovel screening tools, including systems-biology approaches and technologiesdeveloped at Sanford-Burnham, toward the goal of discovering new therapeuticstrategies for reducing insulin resistance in obesity and diabetes.
 
 
Under the three-year agreement, multidisciplinaryteams from Sanford-Burnham and Pfizer will collaborate to identify and validatenew targets for drug discovery. The collaboration reportedly combinesSanford-Burnham's expertise in fundamental disease biology and musclemetabolism with Pfizer's expertise in drug discovery.
 
 
Investigators will utilize Sanford-Burnham'sConrad Prebys Center for Chemical Genomics  to screen for new targets usinginvestigational compounds from Pfizer as well as evaluate compounds previouslyidentified from the NIH chemical library. Once the parties have identifiedcompounds of interest, Sanford-Burnham and Pfizer scientists will collaborateto characterize and further study the promising compounds to understand theirmechanism of action. These compounds will then be used as "probes" to identifynovel therapeutic targets for the treatment of diabetes.
 
 
"Diabetes presents an enormous public healthburden. There is an acute need to translate innovative science into potentialnew medicines for people living with this debilitating disease," said TimRolph, vice president and head of the Cardiovascular and Metabolic DiseasesResearch Unit at Pfizer. "Pfizer's collaboration with Sanford-Burnham touse their cutting-edge screen designs is an example of our strategy to workwith academic innovators to discover novel therapeutics for prevention andtreatment of diabetes."
 
 
"Pfizer will have access to Sanford-Burnham's teamof world-class scientists and translational infrastructure dedicated to findingnew approaches to targeting disease. Collaborating with researchers at a majorpharmaceutical company will help Sanford-Burnham achieve its mission oftranslating high-impact science into new therapies," said Dr. Stephen Gardell, seniordirector of scientific resources at Sanford-Burnham's Lake Nona location. "This importantcollaboration focuses our tremendous scientific and translational firepower ona major medical problem: complications of obesity-related diabetes. Workingwith Pfizer, we can more quickly bridge the gap between basic and translationalresearch."
 
 
SOURCE:Sanford-Burnham news release 

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

GreenCooling

Thermo Scientific™ Centrifuges with GreenCool Technology

Next-generation natural refrigerant cooling system for centrifuges, offering a lower Global Warming Potential and reduced energy consumption.
Clear sample tubes are shown in a clear tote with red lids in a sample prep robot with a blue and silver industrial lab background.

The crucial role of sample preparation in biotherapy manufacturing

Discover how better sample preparation can unlock improved assay accuracy and analytical results.
A black mosquito is shown on pink human skin against a blurred green backdrop.

Discovering deeper insights into malaria research

Malaria continues to drive urgent research worldwide, with new therapies and tools emerging to combat the parasite’s complex lifecycle and global burden.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue